Dr. Richard Maziarz
I've won the following awards
Chair, Financial Committee of Systems Capacity Initiative, National.Marrow Donor Program
Co-Chair, Commercialization Committee, International Society for Cellular Therapy
Top Doctors, Portland Monthly Magazine
Top Doctors, Portland Monthly Magazine
Top Doctors, Castle Connolly Medical
Top Doctor in America, Top Doctors in America
Co-Chair, Chronic Leukemia Working Committee, Center for International Blood & Marrow Transplant Registry
Vice-President for North America Region, International Society of Cellular Therapy
Clinician Scientist Award, American Heart Association
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.
Biol. Blood Marrow Transplant., Nov (2012)
Hematopoietic Cell Transplantation in 2020: Summary of Year II Recommendations of the National Marrow Donor Program's System Capacity Initiative.
Biol. Blood Marrow Transplant., Oct (2012)
Peripheral-blood stem cells versus bone marrow from unrelated donors.
N. Engl. J. Med., Oct;367(16):1487-96 (2012)
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Blood., Nov;120(20):4256-4262 (2012)
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
Br. J. Haematol., Oct;159(1):58-66 (2012)
Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation.
Biol. Blood Marrow Transplant., Dec;18(12):1851-8 (2012)
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of
Biol. Blood Marrow Transplant., Oct;18(10):1564-72 (2012)
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.
Immunotherapy., May;4(5):529-47 (2012)
Lenalidomide after stem-cell transplantation for multiple myeloma.
N. Engl. J. Med., May;366(19):1770-81 (2012)
Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.
Bone Marrow Transplant., Dec;47(12):1526-9 (2012)
No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation.
Transpl Infect Dis., Oct;14(5):468-78 (2012)
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.
Biol. Blood Marrow Transplant., Sep;18(9):1446-54 (2012)
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies.
Biol. Blood Marrow Transplant., Aug;18(8):1302-8 (2012)
The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment.
Biol. Blood Marrow Transplant., Feb;18(2):172-82 (2012)
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
JAMA., Nov;306(17):1874-83 (2011)
Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.
Biol. Blood Marrow Transplant., Jun;18(6):861-73 (2012)
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Bone Marrow Transplant., Jun;47(6):810-6 (2012)
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.
Biol. Blood Marrow Transplant., Feb;18(2):280-8 (2012)
Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results.
Health Serv Res., Dec;46(6pt1):1762-77 (2011)
Hematopoietic stem cell transplantation and implications for cell therapy reimbursement.
Cell Stem Cell., Jun;8(6):609-12 (2011)